Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML

Bone Marrow Transplantation

Volumn 47, Issue 11, 2012, Pages 1436-1441

  Hospital, M A ^a   Thomas, X ^b   Castaigne, S ^c   Raffoux, E ^a   Pautas, C ^d   Gardin, C ^e   Bourhis, J H ^f   Reman, O ^g   De Revel, T ^h   Terre C ^c   Preudhomme, C ⁱ   Fenaux, P ^e   Michallet, M ^b   Socie G ^a   Dombret, H ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ LUMIÈRE LYON 2   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e UNIVERSITÉ PARIS 13   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g CHU Clemenceau   (France)

^h PERCY MILITARY HOSPITAL   (France)

ⁱ UNIV LILLE   (France)

Author keywords

adverse karyotype; AML; methodology

Indexed keywords

CYTARABINE; ETOPOSIDE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME DELETION 11Q23; CHROMOSOME DELETION 3Q26; CHROMOSOME DELETION 5Q; CHROMOSOME DELETION 7Q; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; CUMULATIVE INCIDENCE OF RELAPSE; DONOR SELECTION; DRUG MEGADOSE; FEMALE; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SURVIVAL TIME;

ADOLESCENT; ADULT; AGE FACTORS; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84869084795     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.49     Document Type: Article

References (20)

1. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH et al. The value of allogeneic bone marrow transplantation in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385-400. (Pubitemid 34994639)
2. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC-GIMEMA AML-10 trial. Blood 2003; 102: 1232-1240. (Pubitemid 36988027)
3. Jourdan E, Boiron JM, Dastugue N, Vey N, Marit G, Rigal-Huguet F et al. Early allogeneic stem-cell transplantation for young adults with acute myeloid leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT expérience. J Clin Oncol 2005; 23: 7676-7684.
4. Burnett AK, Wheatley K, Goldstone AH, Stevens R, Hann I, Hills RK. Long-term results of the MRC AML10 trial. Clin Adv Hematol Oncol 2006; 4: 445-451. (Pubitemid 44018490)
5. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLAidentical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007; 109: 3658-3666. (Pubitemid 46641712)
6. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission. Systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301: 2349-2361.
7. Dö hner H, Estey EH, Amadori S, Appelbaum FR, Bü chner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
8. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710-719. (Pubitemid 14202071)
9. +7' induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 2004; 104: 2467-3474.
10. Thomas X, Raffoux E, de Botton S, Pautas C, Arnaud P, de Revel T et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly-diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007; 21: 453-461.
11. Cheson BD, Bennett JM, Kopecky KJ, Bü chner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649. (Pubitemid 46594039)
12. ISCN (International System for Human Cytogenetic Nomenclature). Guidelines for cancer cytogenetics. In: Mittelman F (ed). Supplement to an International System for Human Cytogenetic Nomenclature. Karger: Basel, Switzerland, 1991 pp 1-53.
13. Mantel N, Byar DP. Evaluation of response-time data involving transient states: an illustration using heart-transplant data. J Am Stat Assoc 1974; 69: 81-86.
14. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
15. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091-2101.
16. Stram DO, Sather H, Wang L. Analysis of time to death after transplantation when transplant are only given to patients in remission. Biometrics 1996; 52: 1079-1086. (Pubitemid 26296085)
17. Wheatley K, Gray R. Commentary: Mendelian randomization-an update on its use to evaluate allogeneic stem cell transplantation in leukaemia. Int J Epidemiol 2004; 33: 15-17. (Pubitemid 38500148)
18. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092-1099. (Pubitemid 44154650)
19. Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol 2010; 28: 586-595.
20. Schlenk RF, Dö hner K, Mack S, Stoppel M, Kirá ly F, Gö tze K et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 2010; 28: 4642-4648.